<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975505</url>
  </required_header>
  <id_info>
    <org_study_id>16-20978</org_study_id>
    <nct_id>NCT02975505</nct_id>
  </id_info>
  <brief_title>Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD</brief_title>
  <acronym>PERFORMANCE</acronym>
  <official_title>Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The transition from chronic kidney disease (CKD) to end-stage renal disease ESRD is a&#xD;
      vulnerable and challenging period of time for patients and providers. Suboptimal control of&#xD;
      blood pressure is known to be common in patients with the advanced stages of CKD, and may&#xD;
      contribute to their elevated risk of progression to ESRD, cardiovascular morbidity, and&#xD;
      mortality. This proposal is a pilot randomized controlled trial designed to test whether&#xD;
      intensive blood pressure lowering is feasible and safe in patients with advanced CKD as they&#xD;
      transition to ESRD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The transition from advanced chronic kidney disease (CKD), when estimated glomerular&#xD;
      filtration rate (eGFR) is &lt;=30 mL/min/1.73m2, to end-stage renal disease (ESRD) represents a&#xD;
      vulnerable period, when multiple physiologic and psychosocial changes occur as patients&#xD;
      prepare for either dialysis or kidney transplant. This study is a pilot randomized controlled&#xD;
      trial to test the safety and feasibility of studying strict versus usual BP control in a&#xD;
      population of patients with advanced CKD (eGFR &lt;=30 mL/min/1.73m2), including those with&#xD;
      diabetes. For this pilot study, we will randomize 120 patients with advanced CKD who have&#xD;
      elevated BP to either a home SBP target of &lt;120 mm Hg (intervention group) versus 130-140 mm&#xD;
      Hg (usual care group).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperkalemia</measure>
    <time_frame>Months 1-12 and study end</time_frame>
    <description>Hyperkalemia: This will be defined as a non-hemolyzed potassium ≥6.0 meq/L.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Achieved Blood Pressure</measure>
    <time_frame>Months 4-12 and study end</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Falls and syncope by self-report or based on emergency room visits</measure>
    <time_frame>Months 1-12 and study end</time_frame>
    <description>Falls and syncope: This will be defined based on self-report or if either is the chief complaint for an ER visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>End-stage Renal Disease</measure>
    <time_frame>Month 1 to study end</time_frame>
    <description>Defined as receipt of chronic dialysis or kidney transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants screened who enroll in trial</measure>
    <time_frame>Months 0-12</time_frame>
    <description>Feasibility of enrollment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Bloodpressure</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Strict SBP Target</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target Systolic Blood Pressure &lt;120 mm Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual SBP Target</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Target Systolic Blood Pressure 130-140 mm Hg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Strict blood pressure control</intervention_name>
    <description>Systolic Blood Pressure Target &lt; 120 mm Hg (measured at home)</description>
    <arm_group_label>Strict SBP Target</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adults ≥16 years of age who meet the eGFR eligibility criteria, which will be determined&#xD;
        based on whether participants have&#xD;
&#xD;
          1. at least two eGFR in the last three months that are &lt;=30 mL/min/1.73m2 or&#xD;
&#xD;
          2. prior diagnosis of CKD (per electronic chart review) and at least one eGFR &lt;=30&#xD;
             mL/min/1.73m2&#xD;
&#xD;
          3. history of hypertension&#xD;
&#xD;
          4. mid-arm circumference between 22-37cm (BP cuff size limitation) and be able to provide&#xD;
             consent to participate in our study.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
        Those who:&#xD;
&#xD;
          -  are or are planning to become pregnant, due to inability to take multiple classes of&#xD;
             anti-hypertensive agents&#xD;
&#xD;
          -  are marginally housed, due to concerns regarding routine follow-up&#xD;
&#xD;
          -  are actively participating in a different interventional trial that may affect blood&#xD;
             pressure&#xD;
&#xD;
          -  are unwilling to consent to participate&#xD;
&#xD;
          -  institutionalized individuals or prisoners&#xD;
&#xD;
          -  are actively abusing illicit drugs or alcohol&#xD;
&#xD;
          -  have a history of poor or doubtful compliance (e.g., frequently missed appointments)&#xD;
&#xD;
          -  have office SBP &gt;170 mmHg&#xD;
&#xD;
          -  are already taking &gt;5 anti-hypertensive medications (any classes, including diuretics)&#xD;
             have cognitive impairment prohibiting participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Hsu, MD MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elaine Ku, MD MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine Ku, MD MAS</last_name>
    <phone>415-353-2507</phone>
    <email>Elaine.Ku@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Divya Seth, BA</last_name>
    <phone>916-476-2041</phone>
    <email>divya.seth@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Divya Seth, BA</last_name>
      <phone>916-476-2041</phone>
      <email>divya.seth@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elaine Ku, MD MAS</last_name>
      <email>elaine.ku@ucsf.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

